Maxim Group set a $2.00 target price on Cytori Therapeutics (NASDAQ:CYTX) in a research report report published on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages also recently weighed in on CYTX. ValuEngine raised Cytori Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Laidlaw reaffirmed a buy rating and issued a $1.65 target price on shares of Cytori Therapeutics in a report on Thursday, February 22nd. Zacks Investment Research downgraded Cytori Therapeutics from a hold rating to a sell rating in a report on Thursday, March 8th. Finally, B. Riley raised Cytori Therapeutics from a neutral rating to a buy rating in a report on Friday, March 9th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. Cytori Therapeutics has an average rating of Hold and an average target price of $1.80.
Shares of CYTX stock opened at $0.29 on Wednesday. The firm has a market capitalization of $17.65, a price-to-earnings ratio of -0.44 and a beta of 3.10. Cytori Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $2.08.
In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ag Postfinance sold 286,982 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the sale, the insider now directly owns 5,118,627 shares in the company, valued at approximately $1,586,774.37. The disclosure for this sale can be found here. In the last three months, insiders have sold 695,767 shares of company stock worth $231,951. 1.90% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. lifted its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 134.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,136,041 shares of the biotechnology company’s stock after acquiring an additional 1,223,046 shares during the quarter. Perkins Capital Management Inc. owned approximately 6.08% of Cytori Therapeutics worth $644,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.21% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cytori Therapeutics (CYTX) PT Set at $2.00 by Maxim Group” was first posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2018/03/31/cytori-therapeutics-cytx-pt-set-at-2-00-by-maxim-group.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.